APGE · Apogee Therapeutics, Inc.
$135.07
+0.00% last session
End-of-day data · close of 2026-09-02
Market cap
$10B
Enterprise value
$9B
Trailing P/E
—
Forward P/E
-26.0
Dividend yield
—
Beta
0.33
Avg volume
3M
Employees
0K
Daily Change %
0.00%
5 Days Change
0.10%
10 Days Change
0.53%
30 Days Change
48.22%
60 Days Change
71.15%
Month to Day Change
0.00%
Year to Day Change
77.48%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — APGE
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-13
Latest call per bank · past 12 months
Deutsche Bank
Hold$135
+0.8% vs priceCitigroup
Neutral$135
+0.8% vs priceRBC Capital
Sector Perform$135
+0.8% vs priceUBS
Neutral$135
+0.9% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-13 | Truist Securities | Maintains | Hold | $81.00 → $135 |
| 2026-08-12 | BTIG | Downgrade | Buy → Neutral | $0.00 |
| 2026-06-24 | Stifel | Downgrade | Buy → Hold | $133 → $135 |
| 2026-06-24 | TD Cowen | Downgrade | Buy → Hold | $0.00 |
| 2026-06-24 | Guggenheim | Downgrade | Buy → Neutral | $0.00 |
| 2026-06-24 | Mizuho | Downgrade | Outperform → Neutral | $110 → $135 |
| 2026-06-23 | Deutsche Bank | Downgrade | Buy → Hold | $116 → $135 |
| 2026-06-23 | Citigroup | Downgrade | Buy → Neutral | $125 → $135 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-02
- RSI (14): RSI is 81 — overbought territory; the recent run-up may be due for a pause.
- Price vs 50-day MA: Trading 30.6% above the 50-day MA ($103.40).
- Price vs 200-day MA: Trading 71.1% above the 200-day MA ($78.93).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-1.47) — short-term momentum is fading.
- 52-week range: Price is within 5% of the 52-week high ($135.07).
APGE Price Chart
Loading chart for APGE…
Fundamentals
About Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc. develops and commercializes biologic therapies for immunological and inflammatory (I&I) diseases for patients and caregivers. The company's pipeline includes products, such as ZUMILOKIBART (APG777), a monoclonal antibody for atopic dermatitis, asthma, and eosinophilic esophagitis; APG990, a monoclonal antibody targeting OX40L; APG808, an antibody targeting IL-4Ra for chronic obstructive pulmonary disease and asthma; APG333, a half-life extended TSLP antibody; APG279, a combination therapy for atopic dermatitis; and APG273 for asthma and COPD. It also provides services related to engineering and optimizing antibodies with improved pharmacokinetics to reduce injection frequency for patients. The company was founded in 2022 and is based in San Francisco, California with an additional office in Waltham, Massachusetts. As of September 3, 2026, Apogee Therapeutics, Inc. operates as a subsidiary of AbbVie Inc.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$131B 13.5% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$80B 3.2% YTD
ARGX
argenx SE
$62B 17.0% YTD
MRNA
Moderna, Inc.
$57B 363.3% YTD
RVMD
Revolution Medicines, Inc.
$44B 155.3% YTD
ONC
BeOne Medicines Ltd.
$39B 12.5% YTD
RPRX
Royalty Pharma plc
$34B 54.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -37.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.